Prestige Consumer Healthcare (PBH) Financials

$46.61 -0.14 (-0.30%)

Closing price 05/18/2026 03:59 PM Eastern

Extended Trading

$46.60 -0.01 (-0.03%)

As of 07:03 AM Eastern

Annual Income Statements for Prestige Consumer Healthcare

This table shows Prestige Consumer Healthcare's income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025	2026
Period end date	3/31/2016	3/31/2017	3/31/2018	3/31/2019	3/31/2020	3/31/2021	3/31/2022	3/31/2023	3/31/2024	3/31/2025	3/31/2026
Net Income / (Loss) Attributable to Common Shareholders	100	69	2,422	-36	142	165	205	-82	209	215	190
Consolidated Net Income / (Loss)	100	69	340	-36	142	165	205	-82	209	215	190
Net Income / (Loss) Continuing Operations	100	69	2,422	-36	142	165	205	-82	209	215	190
Total Pre-Tax Income	157	111	107	-38	191	204	262	-94	276	284	257
Total Operating Income	260	206	215	68	291	297	330	-22	342	337	309
Total Gross Profit	467	500	577	556	552	547	621	625	624	634	596
Total Revenue	806	882	3,124	976	963	943	1,087	1,128	1,125	1,138	1,089
Operating Revenue	803	882	1,041	976	963	943	1,087	1,128	1,125	1,138	1,089
Total Cost of Revenue	339	382	465	420	411	396	466	502	501	503	493
Operating Cost of Revenue	339	382	465	420	411	396	466	502	501	503	493
Total Operating Expenses	207	295	361	488	261	250	291	648	282	298	286
Selling, General & Admin Expense	72	89	85	90	89	83	107	107	106	108	116
Marketing Expense	111	128	147	143	147	141	157	145	153	156	149
Depreciation Expense	24	25	28	27	25	24	25	25	23	21	21
Impairment Charge	0.00	0.00	100	229	-	2.43	1.06	370	0.00	12	0.00
Total Other Income / (Expense), net	-103	-95	-108	-106	-100	-93	-67	-72	-66	-53	-52
Interest Expense	103	95	109	105	98	95	66	69	67	48	42
Other Income / (Expense), net	-	-0.03	0.39	-0.48	-1.63	1.37	-1.05	-2.34	0.76	-4.95	-9.57
Income Tax Expense	57	41	-232	-2.26	49	39	57	-12	67	70	67
Basic Earnings per Share	$1.89	$1.31	$6.40	($0.69)	$2.81	$3.28	$4.09	($1.65)	$4.21	$4.32	$3.93
Weighted Average Basic Shares Outstanding	52.75M	52.98M	53.10M	52.07M	50.72M	50.21M	50.26M	49.89M	49.76M	49.70M	48.46M
Diluted Earnings per Share	$1.88	$1.30	$6.34	($0.69)	$2.78	$3.25	$4.04	($1.65)	$4.17	$4.29	$3.91
Weighted Average Diluted Shares Outstanding	53.14M	53.36M	53.53M	52.07M	51.14M	50.61M	50.84M	49.89M	50.18M	50.08M	48.72M
Weighted Average Basic & Diluted Shares Outstanding	52.90M	53M	53.10M	51.90M	50.09M	49.91M	50.28M	49.69M	49.92M	49.41M	47.37M

This table shows Prestige Consumer Healthcare's income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric	Q2 2024	Q3 2024	Q4 2024	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026	Q2 2026	Q3 2026	Q4 2026
Period end date	9/30/2023	12/31/2023	3/31/2024	6/30/2024	9/30/2024	12/31/2024	3/31/2025	6/30/2025	9/30/2025	12/31/2025	3/31/2026
Net Income / (Loss) Attributable to Common Shareholders	54	53	49	49	54	61	50	47	42	47	54
Consolidated Net Income / (Loss)	54	53	49	49	54	61	50	47	42	47	54
Net Income / (Loss) Continuing Operations	54	53	49	49	54	61	50	47	42	47	54
Total Pre-Tax Income	70	70	67	58	72	80	74	62	69	62	65
Total Operating Income	88	87	82	72	84	92	88	72	80	82	75
Total Gross Profit	160	158	152	146	157	161	170	140	152	157	146
Total Revenue	286	283	277	267	284	290	297	250	274	283	282
Operating Revenue	286	283	277	267	284	290	297	250	274	283	282
Total Cost of Revenue	126	125	125	121	126	129	127	109	123	126	135
Operating Cost of Revenue	126	125	125	121	126	129	127	109	123	126	135
Total Operating Expenses	72	71	70	74	73	69	82	69	72	75	71
Selling, General & Admin Expense	26	26	26	29	26	26	27	28	28	30	30
Marketing Expense	40	39	38	39	41	38	37	35	39	40	35
Depreciation Expense	5.67	5.64	5.68	5.70	5.57	4.96	5.06	5.18	5.17	5.15	5.44
Total Other Income / (Expense), net	-18	-17	-15	-14	-13	-12	-14	-9.98	-11	-21	-11
Interest Expense	18	17	15	13	12	11	11	10	10	11	11
Other Income / (Expense), net	-0.23	-0.68	0.43	-0.50	-0.40	-0.35	-3.71	0.22	-0.50	-10	0.71
Income Tax Expense	17	17	18	9.35	17	19	24	14	27	15	11
Basic Earnings per Share	$1.08	$1.07	$0.99	$0.98	$1.10	$1.23	$1.01	$0.96	$0.86	$0.98	$1.13
Weighted Average Basic Shares Outstanding	49.69M	49.74M	49.76M	49.89M	49.65M	49.60M	49.70M	49.48M	49.03M	47.88M	48.46M
Diluted Earnings per Share	$1.07	$1.06	$0.98	$0.98	$1.09	$1.22	$1.00	$0.95	$0.86	$0.97	$1.13
Weighted Average Diluted Shares Outstanding	50.08M	50.13M	50.18M	50.27M	50.00M	49.99M	50.08M	49.83M	49.26M	48.09M	48.72M
Weighted Average Basic & Diluted Shares Outstanding	49.62M	49.65M	49.92M	49.56M	49.41M	49.54M	49.41M	49.21M	48.08M	47.32M	47.37M

This table details how cash moves in and out of Prestige Consumer Healthcare's business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025	2026
Period end date	3/31/2016	3/31/2017	3/31/2018	3/31/2019	3/31/2020	3/31/2021	3/31/2022	3/31/2023	3/31/2024	3/31/2025	3/31/2026
Net Change in Cash & Equivalents	5.91	15	-9.31	-5.02	67	-62	-5.12	31	-12	51	-34
Net Cash From Operating Activities	176	149	210	189	217	236	260	230	249	252	258
Net Cash From Continuing Operating Activities	176	149	210	189	217	236	260	230	249	252	258
Net Income / (Loss) Continuing Operations	100	69	340	-36	142	165	205	-82	209	215	190
Consolidated Net Income / (Loss)	100	69	340	-36	142	165	205	-82	209	215	190
Depreciation Expense	24	26	33	32	29	30	32	33	31	30	31
Amortization Expense	8.99	8.63	6.74	5.92	3.81	4.98	4.23	4.36	5.24	1.75	1.80
Non-Cash Adjustments To Reconcile Net Income	20	64	115	236	11	16	13	383	13	25	21
Changes in Operating Assets and Liabilities, net	24	-19	-285	-49	31	20	5.48	-108	-9.63	-20	13
Net Cash From Investing Activities	-223	-695	-12	55	-17	-22	-257	-12	-20	-17	-137
Net Cash From Continuing Investing Activities	-223	-695	-12	55	-17	-22	-257	-12	-20	-17	-137
Purchase of Property, Plant & Equipment	-3.57	-2.98	-13	-10	-15	-22	-9.64	-7.78	-9.55	-8.22	-11
Acquisitions	-227	-804	0.00	0.00	-2.76	0.00	-	-3.80	-11	-8.25	-124
Other Investing Activities, net	-	-	0.97	0.00	0.75	0.00	-247	-	0.00	-0.98	-1.93
Net Cash From Financing Activities	52	561	-209	-249	-131	-279	-7.57	-186	-241	-182	-156
Net Cash From Continuing Financing Activities	52	561	-209	-249	-131	-279	-7.57	-186	-241	-182	-156
Repayment of Debt	-498	-979	-490	-245	-575	-883	-691	-155	-226	-135	-40
Repurchase of Common Equity	-	0.00	0.00	-50	-57	-12	0.00	-50	-25	-52	-156
Issuance of Debt	545	1,537	280	45	500	615	682	20	0.00	0.00	40
Other Financing Activities, net	4.47	2.60	0.55	0.65	-0.13	0.17	1.54	-0.85	9.75	4.43	0.47
Effect of Exchange Rate Changes	0.50	-	1.10	-0.41	-1.89	3.60	-	-0.98	0.18	-	1.26
Cash Interest Paid	79	85	99	98	92	80	61	54	63	48	44
Cash Income Taxes Paid	15	48	24	33	31	34	47	41	60	52	46

This table details how cash moves in and out of Prestige Consumer Healthcare's business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric	Q2 2024	Q3 2024	Q4 2024	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026	Q2 2026	Q3 2026	Q4 2026
Period end date	9/30/2023	12/31/2023	3/31/2024	6/30/2024	9/30/2024	12/31/2024	3/31/2025	6/30/2025	9/30/2025	12/31/2025	3/31/2026
Net Change in Cash & Equivalents	5.49	3.55	-17	-12	17	-0.67	47	42	-20	-57	1.50
Net Cash From Operating Activities	62	71	67	55	70	65	62	79	57	78	43
Net Cash From Continuing Operating Activities	62	71	67	55	70	65	62	79	57	78	43
Net Income / (Loss) Continuing Operations	54	53	49	49	54	61	50	47	42	47	54
Consolidated Net Income / (Loss)	54	53	49	49	54	61	50	47	42	47	54
Depreciation Expense	7.64	7.65	7.84	8.12	7.93	6.87	7.25	7.67	7.66	7.59	8.35
Amortization Expense	1.32	1.42	1.51	0.45	0.43	0.43	0.44	0.44	0.45	0.45	0.46
Non-Cash Adjustments To Reconcile Net Income	3.70	7.66	3.55	3.87	2.05	2.81	17	3.71	1.91	13	2.71
Changes in Operating Assets and Liabilities, net	-3.76	1.70	4.54	-6.74	5.02	-6.05	-13	20	5.26	10	-23
Net Cash From Investing Activities	-2.93	-4.50	-15	-2.13	-2.03	-9.82	-3.48	-1.94	-2.93	-129	-3.41
Net Cash From Continuing Investing Activities	-2.93	-4.50	-15	-2.13	-2.03	-9.82	-3.48	-1.94	-2.93	-129	-3.41
Purchase of Property, Plant & Equipment	-2.93	-2.00	-3.14	-1.15	-2.03	-1.57	-3.48	-0.84	-2.10	-3.03	-5.21
Acquisitions	-	-	-	-	-	-	-	-	-	-	1.80
Net Cash From Financing Activities	-54	-65	-68	-66	-51	-54	-11	-36	-75	-6.73	-38
Net Cash From Continuing Financing Activities	-54	-65	-68	-66	-51	-54	-11	-36	-75	-6.73	-38
Repayment of Debt	-55	-66	-75	-35	-40	-60	-	0.00	-	-0.25	-40
Repurchase of Common Equity	-	-	-	-26	-12	-2.40	-11	-35	-75	-46	-0.69
Other Financing Activities, net	1.45	0.93	6.56	-4.55	0.62	8.54	-0.18	-1.51	0.05	-0.67	2.59
Cash Interest Paid	16	16	14	14	12	12	10	12	10	11	11
Cash Income Taxes Paid	13	13	21	3.66	15	15	19	3.25	22	12	9.06

This table presents Prestige Consumer Healthcare's assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025	2026
Period end date	3/31/2016	3/31/2017	3/31/2018	3/31/2019	3/31/2020	3/31/2021	3/31/2022	3/31/2023	3/31/2024	3/31/2025	3/31/2026
Total Assets	2,949	3,911	3,761	3,441	3,514	3,429	3,671	3,354	3,318	3,402	3,494
Total Current Assets	249	334	303	301	366	270	293	392	375	448	431
Cash & Equivalents	27	42	33	28	95	32	27	58	46	98	64
Accounts Receivable	95	137	141	149	151	115	139	167	177	194	192
Inventories, net	91	116	119	120	116	115	120	162	139	148	159
Prepaid Expenses	25	40	12	4.74	4.35	7.90	6.41	4.12	13	8.44	17
Plant, Property, & Equipment, net	16	51	53	51	56	70	71	70	77	75	122
Total Noncurrent Assets	2,684	3,526	3,405	3,089	3,092	3,089	3,306	2,892	2,867	2,879	2,941
Noncurrent Note & Lease Receivables	-	-	-	0.00	5.84	8.99	6.86	4.20	1.54	25	22
Goodwill	360	615	620	579	575	578	579	528	528	527	581
Intangible Assets	2,323	2,904	2,781	2,507	2,479	2,476	2,697	2,342	2,321	2,295	2,300
Other Noncurrent Operating Assets	1.32	7.45	3.57	3.13	32	27	24	18	17	32	39
Total Liabilities & Shareholders' Equity	2,949	3,911	3,761	3,441	3,514	3,429	3,671	3,354	3,318	3,402	3,494
Total Liabilities	2,204	3,089	2,582	2,345	2,343	2,071	2,093	1,907	1,663	1,567	1,607
Total Current Liabilities	107	162	123	127	150	122	143	161	117	107	121
Accounts Payable	38	70	61	57	62	46	56	63	39	19	23
Accrued Expenses	60	84	52	61	71	61	74	73	56	63	73
Dividends Payable	8.66	8.13	9.71	9.76	9.91	6.31	4.44	16	16	16	16
Other Current Liabilities	-	-	-	0.00	6.83	8.45	9.11	9.76	6.15	8.54	9.57
Total Noncurrent Liabilities	2,098	2,927	2,459	2,218	2,193	1,949	1,950	1,746	1,546	1,461	1,486
Long-Term Debt	1,625	2,194	1,993	1,799	1,730	1,480	1,477	1,346	1,126	992	994
Capital Lease Obligations	-	-	-	0.00	30	27	21	12	7.70	43	39
Noncurrent Deferred & Payable Income Tax Liabilities	470	715	443	400	408	434	445	380	404	420	447
Other Noncurrent Operating Liabilities	2.84	18	23	20	25	8.61	7.48	8.17	9.19	5.39	5.58
Commitments & Contingencies	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Equity & Noncontrolling Interests	744	823	1,179	1,096	1,171	1,358	1,578	1,447	1,655	1,835	1,888
Total Preferred & Common Equity	744	823	1,179	1,096	1,171	1,358	1,578	1,447	1,655	1,835	1,888
Preferred Stock	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Common Equity	744	823	1,179	1,096	1,171	1,358	1,578	1,447	1,655	1,835	1,888
Common Stock	446	459	469	480	489	500	516	536	568	594	609
Retained Earnings	327	397	736	702	844	1,009	1,214	1,132	1,341	1,556	1,746
Treasury Stock	-5.16	-6.59	-7.67	-60	-118	-131	-134	-189	-220	-277	-439
Accumulated Other Comprehensive Income / (Loss)	-24	-26	-19	-26	-44	-20	-19	-32	-34	-38	-28

This table presents Prestige Consumer Healthcare's assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric	Q2 2023	Q3 2023	Q1 2024	Q2 2024	Q3 2024	Q1 2025	Q2 2025	Q3 2025	Q1 2026	Q2 2026	Q3 2026
Period end date	9/30/2022	12/31/2022	6/30/2023	9/30/2023	12/31/2023	6/30/2024	9/30/2024	12/31/2024	6/30/2025	9/30/2025	12/31/2025
Total Assets	3,679	3,750	3,346	3,333	3,340	3,308	3,317	3,329	3,432	3,442	3,495
Total Current Assets	337	409	392	388	394	369	381	377	481	497	433
Cash & Equivalents	42	86	55	60	64	34	52	51	140	119	62
Accounts Receivable	146	157	158	158	174	172	164	167	168	199	190
Inventories, net	141	159	170	161	149	152	156	152	153	159	164
Prepaid Expenses	7.71	6.89	9.38	8.39	7.25	11	9.40	7.50	19	20	17
Plant, Property, & Equipment, net	70	70	70	71	70	75	75	74	74	73	128
Total Noncurrent Assets	3,272	3,271	2,884	2,874	2,876	2,863	2,861	2,879	2,877	2,872	2,933
Noncurrent Note & Lease Receivables	5.53	4.86	3.54	2.87	2.21	0.88	0.21	4.94	24	23	23
Goodwill	576	577	527	527	528	528	529	527	528	528	581
Intangible Assets	2,671	2,670	2,336	2,328	2,329	2,318	2,317	2,311	2,295	2,291	2,302
Other Noncurrent Operating Assets	20	20	17	16	17	16	15	36	30	29	28
Total Liabilities & Shareholders' Equity	3,679	3,750	3,346	3,333	3,340	3,308	3,317	3,329	3,432	3,442	3,495
Total Liabilities	2,059	2,063	1,865	1,797	1,739	1,627	1,585	1,541	1,576	1,617	1,665
Total Current Liabilities	152	160	147	130	127	114	107	103	110	135	140
Accounts Payable	56	64	58	44	39	40	31	20	22	42	43
Accrued Expenses	71	71	65	60	65	55	57	61	64	68	73
Dividends Payable	16	15	15	16	15	15	16	15	15	16	15
Other Current Liabilities	9.44	9.67	9.46	9.61	7.84	4.45	2.65	6.92	8.60	8.62	8.63
Total Noncurrent Liabilities	1,906	1,903	1,718	1,667	1,612	1,513	1,478	1,439	1,466	1,483	1,526
Long-Term Debt	1,438	1,424	1,317	1,263	1,199	1,091	1,052	992	993	993	1,034
Capital Lease Obligations	3.09	14	9.16	0.22	6.33	7.20	0.13	28	41	39	37
Noncurrent Deferred & Payable Income Tax Liabilities	443	456	384	388	397	409	415	413	427	445	449
Other Noncurrent Operating Liabilities	22	8.87	8.18	16	8.92	5.14	12	5.03	5.41	5.38	5.75
Commitments & Contingencies	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Equity & Noncontrolling Interests	1,620	1,687	1,480	1,536	1,601	1,681	1,732	1,788	1,855	1,825	1,829
Total Preferred & Common Equity	1,620	1,687	1,480	1,536	1,601	1,681	1,732	1,788	1,855	1,825	1,829
Preferred Stock	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Common Equity	1,620	1,687	1,480	1,536	1,601	1,681	1,732	1,788	1,855	1,825	1,829
Common Stock	525	533	547	553	557	573	577	589	601	603	606
Retained Earnings	1,320	1,372	1,185	1,239	1,292	1,390	1,445	1,506	1,603	1,645	1,692
Treasury Stock	-189	-189	-220	-220	-220	-252	-263	-266	-316	-392	-439
Accumulated Other Comprehensive Income / (Loss)	-36	-29	-32	-36	-29	-31	-27	-40	-32	-32	-30

This table displays calculated financial ratios and metrics derived from Prestige Consumer Healthcare's official financial filings.

Metric	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025	2026
Period end date	3/31/2016	3/31/2017	3/31/2018	3/31/2019	3/31/2020	3/31/2021	3/31/2022	3/31/2023	3/31/2024	3/31/2025	3/31/2026
DEI Shares Outstanding	-	-	-	-	-	-	-	-	-	-	47,318,730.00
DEI Adjusted Shares Outstanding	-	-	-	-	-	-	-	-	-	-	47,318,730.00
DEI Earnings Per Adjusted Shares Outstanding	-	-	-	-	-	-	-	-	-	-	4.02
Growth Metrics	-	-	-	-	-	-	-	-	-	-	-
Revenue Growth	12.82%	9.40%	254.12%	-68.76%	-1.31%	-2.04%	15.21%	3.76%	-0.21%	1.10%	-4.31%
EBITDA Growth	24.54%	-18.07%	6.66%	-59.10%	207.78%	3.59%	9.37%	-96.65%	2,997.73%	-4.05%	-8.48%
EBIT Growth	24.74%	-21.01%	4.99%	-68.95%	331.96%	3.19%	10.07%	-107.53%	1,486.55%	-3.31%	-9.64%
NOPAT Growth	29.83%	-22.19%	430.74%	-93.08%	358.64%	10.72%	7.59%	-106.08%	1,755.14%	-2.07%	-10.09%
Net Income Growth	27.66%	-30.54%	389.33%	-110.54%	497.43%	15.74%	24.71%	-140.07%	354.34%	2.52%	-11.33%
EPS Growth	26.17%	-30.85%	387.69%	-110.88%	502.90%	16.91%	24.31%	-140.84%	352.73%	2.88%	-8.86%
Operating Cash Flow Growth	12.83%	-15.68%	41.32%	-9.91%	14.71%	8.51%	10.32%	-11.62%	8.36%	1.04%	2.43%
Free Cash Flow Firm Growth	98.94%	-8,194.20%	202.86%	-38.25%	-22.51%	-0.02%	-81.99%	516.93%	-4.14%	-15.06%	-35.20%
Invested Capital Growth	7.87%	26.86%	5.57%	-8.64%	-1.07%	-0.26%	7.53%	-9.52%	-0.14%	1.11%	3.00%
Revenue Q/Q Growth	2.26%	3.86%	204.47%	-72.56%	106.12%	-1.69%	2.76%	1.71%	-0.78%	1.75%	-1.35%
EBITDA Q/Q Growth	1.77%	-4.90%	-22.74%	-55.68%	205.15%	2.55%	1.73%	-96.69%	2,235.94%	0.13%	-2.17%
EBIT Q/Q Growth	1.57%	-5.61%	-25.99%	-66.06%	300.47%	2.66%	1.62%	-107.44%	1,820.83%	0.65%	-2.76%
NOPAT Q/Q Growth	0.02%	-4.57%	7.10%	-66.90%	327.49%	6.28%	2.25%	-105.92%	1,890.46%	-0.17%	1.44%
Net Income Q/Q Growth	-8.96%	-3.94%	-13.01%	-156.12%	686.53%	5.27%	8.78%	-139.13%	359.50%	0.31%	2.04%
EPS Q/Q Growth	-9.62%	-3.70%	-13.03%	-156.10%	795.00%	5.86%	8.60%	-139.57%	359.01%	0.47%	3.44%
Operating Cash Flow Q/Q Growth	-6.50%	-17.86%	28.75%	-1.86%	2.49%	1.27%	1.58%	-1.77%	3.29%	-1.97%	-6.87%
Free Cash Flow Firm Q/Q Growth	-102.21%	-589.49%	218.73%	2.22%	-8.82%	4.24%	13.03%	7.14%	-6.41%	-6.61%	-0.41%
Invested Capital Q/Q Growth	10.46%	38.05%	-2.64%	-6.13%	0.08%	0.22%	0.23%	-9.57%	0.00%	0.56%	0.68%
Profitability Metrics	-	-	-	-	-	-	-	-	-	-	-
Gross Margin	57.95%	56.72%	18.46%	56.94%	57.34%	58.03%	57.11%	55.45%	55.49%	55.76%	54.71%
EBITDA Margin	36.34%	27.21%	8.20%	10.73%	33.47%	35.40%	33.60%	1.09%	33.69%	31.97%	30.58%
Operating Margin	32.29%	23.31%	6.90%	6.92%	30.23%	31.53%	30.36%	-1.99%	30.43%	29.60%	28.42%
EBIT Margin	32.29%	23.31%	6.91%	6.87%	30.07%	31.67%	30.26%	-2.19%	30.50%	29.16%	27.54%
Profit (Net Income) Margin	12.39%	7.87%	10.87%	-3.67%	14.77%	17.46%	18.90%	-7.30%	18.60%	18.86%	17.48%
Tax Burden Percent	63.56%	62.60%	317.10%	94.07%	74.43%	80.68%	78.25%	87.64%	75.84%	75.51%	73.90%
Interest Burden Percent	60.38%	53.91%	49.61%	-56.78%	66.02%	68.32%	79.81%	379.44%	80.43%	85.65%	85.88%
Effective Tax Rate	36.44%	37.40%	-217.10%	0.00%	25.57%	19.32%	21.75%	0.00%	24.16%	24.49%	26.10%
Return on Invested Capital (ROIC)	7.30%	4.83%	22.29%	1.57%	7.57%	8.44%	8.77%	-0.54%	9.41%	9.17%	8.08%
ROIC Less NNEP Spread (ROIC-NNEP)	3.15%	1.68%	5.64%	-2.86%	3.27%	3.67%	5.19%	-5.32%	5.24%	5.31%	4.12%
Return on Net Nonoperating Assets (RNNOA)	7.26%	4.03%	11.65%	-4.72%	4.98%	4.58%	5.23%	-4.90%	4.09%	3.13%	2.15%
Return on Equity (ROE)	14.56%	8.86%	33.94%	-3.15%	12.55%	13.02%	13.99%	-5.44%	13.50%	12.30%	10.22%
Cash Return on Invested Capital (CROIC)	-0.27%	-18.85%	16.87%	10.60%	8.65%	8.70%	1.51%	9.45%	9.55%	8.07%	5.12%
Operating Return on Assets (OROA)	9.31%	5.99%	5.63%	1.86%	8.33%	8.61%	9.26%	-0.70%	10.29%	9.87%	8.70%
Return on Assets (ROA)	3.57%	2.02%	8.85%	-0.99%	4.09%	4.74%	5.79%	-2.34%	6.28%	6.39%	5.52%
Return on Common Equity (ROCE)	14.56%	8.86%	33.94%	-3.15%	12.55%	13.02%	13.99%	-5.44%	13.50%	12.30%	10.22%
Return on Equity Simple (ROE_SIMPLE)	13.42%	8.44%	28.81%	-3.27%	12.15%	12.12%	13.02%	-5.69%	12.65%	11.70%	0.00%
Net Operating Profit after Tax (NOPAT)	165	129	683	47	217	240	258	-16	260	254	229
NOPAT Margin	20.52%	14.60%	21.87%	4.84%	22.50%	25.44%	23.75%	-1.39%	23.08%	22.35%	21.00%
Net Nonoperating Expense Percent (NNEP)	4.15%	3.15%	16.64%	4.43%	4.31%	4.77%	3.57%	4.78%	4.17%	3.86%	3.96%
Return On Investment Capital (ROIC_SIMPLE)	-	-	-	-	-	-	-	-	-	8.86%	7.83%
Cost of Revenue to Revenue	42.05%	43.28%	14.88%	43.06%	42.66%	41.97%	42.89%	44.55%	44.51%	44.24%	45.29%
SG&A Expenses to Revenue	8.98%	10.10%	2.73%	9.20%	9.25%	8.81%	9.89%	9.52%	9.43%	9.51%	10.70%
R&D to Revenue	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Operating Expenses to Revenue	25.66%	33.40%	11.56%	50.02%	27.11%	26.51%	26.75%	57.44%	25.06%	26.16%	26.29%
Earnings before Interest and Taxes (EBIT)	260	206	216	67	290	299	329	-25	343	332	300
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)	293	240	256	105	322	334	365	12	379	364	333
Valuation Ratios	-	-	-	-	-	-	-	-	-	-	-
Price to Book Value (P/BV)	3.74	3.53	1.50	1.41	1.57	1.62	1.68	2.15	2.18	2.32	1.49
Price to Tangible Book Value (P/TBV)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Price to Revenue (P/Rev)	3.45	3.29	0.57	1.59	1.91	2.33	2.45	2.76	3.20	3.74	2.58
Price to Earnings (P/E)	27.84	41.86	0.73	0.00	12.96	13.35	12.94	0.00	17.21	19.84	14.74
Dividend Yield	0.00%	0.00%	0.00%	1.59%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Earnings Yield	3.59%	2.39%	137.11%	0.00%	7.72%	7.49%	7.73%	0.00%	5.81%	5.04%	6.79%
Enterprise Value to Invested Capital (EV/IC)	1.86	1.70	1.18	1.15	1.23	1.29	1.35	1.60	1.70	1.86	1.31
Enterprise Value to Revenue (EV/Rev)	5.43	5.73	1.19	3.40	3.64	3.89	3.80	3.91	4.17	4.57	3.47
Enterprise Value to EBITDA (EV/EBITDA)	14.95	21.07	14.56	31.70	10.89	11.00	11.30	360.42	12.37	14.29	11.34
Enterprise Value to EBIT (EV/EBIT)	16.83	24.59	17.26	49.54	12.12	12.29	12.55	0.00	13.66	15.66	12.59
Enterprise Value to NOPAT (EV/NOPAT)	26.47	39.28	5.45	70.27	16.19	15.30	15.99	0.00	18.06	20.43	16.50
Enterprise Value to Operating Cash Flow (EV/OCF)	24.84	34.01	17.74	17.54	16.16	15.58	15.88	19.20	18.84	20.66	14.65
Enterprise Value to Free Cash Flow (EV/FCFF)	0.00	0.00	7.21	10.40	14.18	14.84	92.66	16.05	17.80	23.22	26.03
Leverage & Solvency	-	-	-	-	-	-	-	-	-	-	-
Debt to Equity	2.18	2.67	1.69	1.64	1.50	1.11	0.95	0.94	0.68	0.56	0.55
Long-Term Debt to Equity	2.18	2.67	1.69	1.64	1.50	1.11	0.95	0.94	0.68	0.56	0.55
Financial Leverage	2.30	2.40	2.06	1.65	1.52	1.25	1.01	0.92	0.78	0.59	0.52
Leverage Ratio	4.08	4.38	3.83	3.17	3.07	2.75	2.42	2.32	2.15	1.93	1.85
Compound Leverage Factor	2.46	2.36	1.90	-1.80	2.03	1.88	1.93	8.81	1.73	1.65	1.59
Debt to Total Capital	68.59%	72.73%	62.84%	62.14%	60.05%	52.58%	48.69%	48.40%	40.65%	36.08%	35.37%
Short-Term Debt to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Long-Term Debt to Total Capital	68.59%	72.73%	62.84%	62.14%	60.05%	52.58%	48.69%	48.40%	40.65%	36.08%	35.37%
Preferred Equity to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Noncontrolling Interests to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Common Equity to Total Capital	31.41%	27.27%	37.16%	37.86%	39.95%	47.42%	51.31%	51.60%	59.35%	63.92%	64.63%
Debt to EBITDA	5.55	9.14	7.78	17.17	5.46	4.51	4.10	110.91	2.99	2.85	3.10
Net Debt to EBITDA	5.45	8.96	7.66	16.91	5.17	4.41	4.03	106.13	2.87	2.58	2.91
Long-Term Debt to EBITDA	5.55	9.14	7.78	17.17	5.46	4.51	4.10	110.91	2.99	2.85	3.10
Debt to NOPAT	9.82	17.04	2.92	38.06	8.12	6.28	5.80	-86.51	4.36	4.07	4.52
Net Debt to NOPAT	9.66	16.72	2.87	37.48	7.68	6.14	5.69	-82.78	4.19	3.69	4.24
Long-Term Debt to NOPAT	9.82	17.04	2.92	38.06	8.12	6.28	5.80	-86.51	4.36	4.07	4.52
Altman Z-Score	1.54	1.16	1.76	1.09	1.43	1.66	1.87	1.85	2.64	3.05	2.45
Noncontrolling Interest Sharing Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Liquidity Ratios	-	-	-	-	-	-	-	-	-	-	-
Current Ratio	2.33	2.06	2.46	2.37	2.44	2.21	2.04	2.44	3.20	4.20	3.57
Quick Ratio	1.15	1.10	1.41	1.39	1.64	1.20	1.16	1.40	1.91	2.74	2.12
Cash Flow Metrics	-	-	-	-	-	-	-	-	-	-	-
Free Cash Flow to Firm (FCFF)	-6.06	-503	517	319	247	247	45	275	263	224	145
Operating Cash Flow to CapEx	5,468.67%	5,140.80%	1,676.59%	1,806.15%	1,491.24%	1,059.24%	2,695.73%	2,951.13%	2,606.56%	3,058.31%	2,304.77%
Free Cash Flow to Firm to Interest Expense	-0.06	-5.29	4.74	3.04	2.52	2.61	0.67	3.97	3.92	4.70	3.42
Operating Cash Flow to Interest Expense	1.71	1.57	1.92	1.80	2.21	2.49	3.91	3.32	3.71	5.28	6.08
Operating Cash Flow Less CapEx to Interest Expense	1.68	1.54	1.81	1.70	2.06	2.25	3.77	3.21	3.56	5.11	5.82
Efficiency Ratios	-	-	-	-	-	-	-	-	-	-	-
Asset Turnover	0.29	0.26	0.81	0.27	0.28	0.27	0.31	0.32	0.34	0.34	0.32
Accounts Receivable Turnover	8.81	7.60	22.50	6.74	6.44	7.11	8.56	7.36	6.55	6.13	5.64
Inventory Turnover	4.10	3.69	3.97	3.52	3.48	3.43	3.96	3.56	3.33	3.51	3.21
Fixed Asset Turnover	55.06	26.67	60.56	18.81	17.97	14.97	15.38	15.92	15.32	15.06	11.10
Accounts Payable Turnover	8.03	7.04	7.06	7.13	6.91	7.31	9.16	8.48	9.85	17.38	23.64
Days Sales Outstanding (DSO)	41.45	48.00	16.22	54.18	56.72	51.30	42.65	49.58	55.75	59.52	64.74
Days Inventory Outstanding (DIO)	88.96	98.89	91.96	103.55	104.81	106.48	92.12	102.60	109.61	103.86	113.56
Days Payable Outstanding (DPO)	45.44	51.87	51.69	51.23	52.84	49.95	39.83	43.04	37.06	21.00	15.44
Cash Conversion Cycle (CCC)	84.97	95.02	56.50	106.50	108.69	107.83	94.94	109.13	128.30	142.38	162.86
Capital & Investment Metrics	-	-	-	-	-	-	-	-	-	-	-
Invested Capital	2,351	2,983	3,149	2,877	2,846	2,838	3,052	2,762	2,758	2,788	2,872
Invested Capital Turnover	0.36	0.33	1.02	0.32	0.34	0.33	0.37	0.39	0.41	0.41	0.38
Increase / (Decrease) in Invested Capital	172	631	166	-272	-31	-7.44	214	-290	-3.73	31	84
Enterprise Value (EV)	4,380	5,057	3,727	3,320	3,509	3,672	4,128	4,411	4,690	5,197	3,774
Market Capitalization	2,782	2,905	1,766	1,549	1,844	2,198	2,658	3,112	3,603	4,259	2,805
Book Value per Share	$14.11	$15.54	$22.22	$21.16	$23.30	$27.24	$31.43	$29.12	$33.34	$37.04	$39.89
Tangible Book Value per Share	($36.75)	($50.94)	($41.90)	($38.42)	($37.47)	($34.00)	($33.83)	($28.63)	($24.03)	($19.94)	($20.99)
Total Capital	2,370	3,016	3,172	2,894	2,931	2,864	3,075	2,804	2,789	2,871	2,920
Total Debt	1,625	2,194	1,993	1,799	1,760	1,506	1,497	1,357	1,134	1,036	1,033
Total Long-Term Debt	1,625	2,194	1,993	1,799	1,760	1,506	1,497	1,357	1,134	1,036	1,033
Net Debt	1,598	2,152	1,960	1,771	1,665	1,474	1,470	1,299	1,087	938	969
Capital Expenditures (CapEx)	3.22	2.89	13	10	15	22	9.64	7.78	9.55	8.22	11
Debt-free, Cash-free Net Working Capital (DFCFNWC)	115	131	148	146	121	115	123	173	212	244	247
Debt-free Net Working Capital (DFNWC)	142	172	180	174	216	148	150	231	258	342	311
Net Working Capital (NWC)	142	172	180	174	216	148	150	231	258	342	311
Net Nonoperating Expense (NNE)	66	59	344	83	74	75	53	67	50	40	38
Net Nonoperating Obligations (NNO)	1,607	2,160	1,970	1,781	1,675	1,480	1,474	1,315	1,103	954	985
Total Depreciation and Amortization (D&A)	33	34	40	38	33	35	36	37	36	32	33
Debt-free, Cash-free Net Working Capital to Revenue	14.28%	14.80%	4.73%	15.01%	12.57%	12.23%	11.29%	15.30%	18.80%	21.43%	22.66%
Debt-free Net Working Capital to Revenue	17.65%	19.55%	5.77%	17.83%	22.41%	15.66%	13.79%	20.49%	22.93%	30.03%	28.53%
Net Working Capital to Revenue	17.65%	19.55%	5.77%	17.83%	22.41%	15.66%	13.79%	20.49%	22.93%	30.03%	28.53%
Earnings Adjustments	-	-	-	-	-	-	-	-	-	-	-
Adjusted Basic Earnings per Share	$1.89	$1.31	$6.40	($0.69)	$2.81	$3.28	$4.09	($1.65)	$4.21	$4.32	$3.93
Adjusted Weighted Average Basic Shares Outstanding	52.75M	52.98M	53.10M	52.07M	50.72M	50.21M	50.26M	49.89M	49.76M	49.70M	48.46M
Adjusted Diluted Earnings per Share	$1.88	$1.30	$6.34	($0.69)	$2.78	$3.25	$4.04	($1.65)	$4.17	$4.29	$3.91
Adjusted Weighted Average Diluted Shares Outstanding	53.14M	53.36M	53.53M	52.07M	51.14M	50.61M	50.84M	49.89M	50.18M	50.08M	48.72M
Adjusted Basic & Diluted Earnings per Share	$0.00	$0.00	$0.00	($0.69)	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding	52.76M	52.96M	53.07M	51.80M	50.09M	49.91M	50.28M	49.69M	49.92M	49.41M	47.37M
Normalized Net Operating Profit after Tax (NOPAT)	165	129	221	208	217	242	259	243	260	264	229
Normalized NOPAT Margin	20.52%	14.60%	7.07%	21.30%	22.50%	25.64%	23.83%	21.59%	23.08%	23.18%	21.00%
Pre Tax Income Margin	19.50%	12.57%	3.43%	-3.90%	19.85%	21.64%	24.15%	-8.33%	24.53%	24.98%	23.65%
Debt Service Ratios	-	-	-	-	-	-	-	-	-	-	-
EBIT to Interest Expense	2.52	2.17	1.98	0.64	2.94	3.16	4.95	-0.36	5.11	6.97	7.08
NOPAT to Interest Expense	1.60	1.36	6.26	0.45	2.20	2.54	3.89	-0.23	3.87	5.34	5.40
EBIT Less CapEx to Interest Expense	2.49	2.13	1.86	0.54	2.80	2.92	4.81	-0.47	4.97	6.79	6.82
NOPAT Less CapEx to Interest Expense	1.57	1.33	6.14	0.35	2.05	2.30	3.74	-0.34	3.72	5.17	5.14
Payout Ratios	-	-	-	-	-	-	-	-	-	-	-
Dividend Payout Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Augmented Payout Ratio	0.00%	0.00%	0.00%	-139.60%	39.87%	7.21%	0.00%	-60.75%	11.94%	24.00%	82.12%

This table displays calculated financial ratios and metrics derived from Prestige Consumer Healthcare's official financial filings.

Metric	Q2 2024	Q3 2024	Q4 2024	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026	Q2 2026	Q3 2026	Q4 2026
Period end date	9/30/2023	12/31/2023	3/31/2024	6/30/2024	9/30/2024	12/31/2024	3/31/2025	6/30/2025	9/30/2025	12/31/2025	3/31/2026
DEI Shares Outstanding	-	-	-	-	-	-	-	-	-	-	47,318,730.00
DEI Adjusted Shares Outstanding	-	-	-	-	-	-	-	-	-	-	47,318,730.00
DEI Earnings Per Adjusted Shares Outstanding	-	-	-	-	-	-	-	-	-	-	1.14
Growth Metrics	-	-	-	-	-	-	-	-	-	-	-
Revenue Growth	-1.02%	2.62%	-3.11%	-4.36%	-0.88%	2.68%	7.05%	-6.59%	-3.41%	-2.37%	-5.03%
EBITDA Growth	4.52%	0.25%	133.93%	-15.62%	-4.83%	3.88%	0.51%	-0.05%	-5.44%	-18.58%	-8.01%
EBIT Growth	5.32%	0.13%	129.44%	-17.22%	-4.63%	6.34%	2.59%	0.60%	-5.69%	-20.87%	-10.05%
NOPAT Growth	3.82%	-0.44%	130.68%	-8.38%	-4.66%	5.77%	-0.69%	-8.90%	-23.99%	-11.01%	4.87%
Net Income Growth	4.97%	2.11%	120.56%	-7.90%	1.53%	15.05%	1.35%	-3.26%	-22.37%	-23.49%	7.58%
EPS Growth	4.90%	1.92%	120.42%	-7.55%	1.87%	15.09%	2.04%	-3.06%	-21.10%	-20.49%	13.00%
Operating Cash Flow Growth	8.55%	30.09%	13.43%	13.91%	11.75%	-8.93%	-7.56%	44.25%	-17.64%	20.27%	-30.73%
Free Cash Flow Firm Growth	429.85%	525.76%	-31.68%	-80.23%	-79.51%	-84.85%	-54.14%	-25.33%	-40.28%	-131.92%	-170.84%
Invested Capital Growth	-9.22%	-9.69%	-0.14%	-0.24%	-0.26%	0.55%	1.11%	0.18%	0.23%	2.88%	3.00%
Revenue Q/Q Growth	2.51%	-1.25%	-2.03%	-3.56%	6.23%	2.30%	2.14%	-15.85%	9.85%	3.40%	-0.64%
EBITDA Q/Q Growth	2.13%	-1.82%	-3.45%	-12.85%	15.19%	7.16%	-6.57%	-13.33%	8.98%	-7.73%	5.56%
EBIT Q/Q Growth	1.84%	-2.13%	-4.14%	-13.36%	17.32%	9.13%	-7.52%	-15.04%	9.99%	-8.44%	5.12%
NOPAT Q/Q Growth	1.62%	-1.37%	-8.84%	0.28%	5.74%	9.42%	-14.41%	-8.01%	-11.77%	28.10%	0.86%
Net Income Q/Q Growth	0.53%	-0.96%	-6.76%	-0.79%	10.82%	12.24%	-17.87%	-5.31%	-11.07%	10.63%	15.49%
EPS Q/Q Growth	0.94%	-0.93%	-7.55%	0.00%	11.22%	11.93%	-18.03%	-5.00%	-9.47%	12.79%	16.49%
Operating Cash Flow Q/Q Growth	29.89%	14.43%	-6.39%	-18.13%	27.43%	-6.75%	-4.98%	27.75%	-27.24%	36.18%	-45.28%
Free Cash Flow Firm Q/Q Growth	2.17%	4.40%	-82.31%	4.74%	5.88%	-22.79%	-46.45%	70.56%	-15.33%	-141.28%	-18.85%
Invested Capital Q/Q Growth	-0.44%	0.11%	0.00%	0.08%	-0.45%	0.92%	0.56%	-0.83%	-0.41%	3.59%	0.68%
Profitability Metrics	-	-	-	-	-	-	-	-	-	-	-
Gross Margin	55.89%	55.86%	54.81%	54.66%	55.46%	55.47%	57.34%	56.24%	55.30%	55.52%	51.95%
EBITDA Margin	33.87%	33.68%	33.19%	29.99%	32.53%	34.07%	31.16%	32.10%	31.84%	28.41%	30.19%
Operating Margin	30.82%	30.71%	29.66%	26.97%	29.72%	31.68%	29.82%	28.76%	29.06%	29.10%	26.81%
EBIT Margin	30.74%	30.47%	29.81%	26.78%	29.58%	31.55%	28.57%	28.85%	28.88%	25.57%	27.06%
Profit (Net Income) Margin	18.71%	18.76%	17.86%	18.37%	19.16%	21.02%	16.91%	19.02%	15.40%	16.47%	19.15%
Tax Burden Percent	76.06%	76.24%	73.46%	84.00%	75.88%	76.14%	67.78%	76.83%	61.06%	75.54%	83.26%
Interest Burden Percent	80.00%	80.76%	81.52%	81.64%	85.37%	87.50%	87.30%	85.83%	87.32%	85.28%	85.00%
Effective Tax Rate	23.94%	23.76%	26.54%	16.00%	24.12%	23.86%	32.22%	23.17%	38.94%	24.46%	16.74%
Return on Invested Capital (ROIC)	9.13%	9.14%	8.89%	9.13%	9.10%	9.75%	8.29%	8.96%	7.16%	8.63%	8.59%
ROIC Less NNEP Spread (ROIC-NNEP)	8.10%	8.10%	7.98%	8.16%	8.24%	8.91%	7.34%	8.19%	6.50%	7.07%	7.66%
Return on Net Nonoperating Assets (RNNOA)	6.76%	6.22%	6.22%	6.11%	5.64%	5.63%	4.32%	4.61%	3.56%	3.92%	3.99%
Return on Equity (ROE)	15.89%	15.36%	15.11%	15.23%	14.74%	15.39%	12.62%	13.56%	10.72%	12.55%	12.58%
Cash Return on Invested Capital (CROIC)	9.17%	9.69%	9.55%	9.44%	9.38%	8.66%	8.07%	8.84%	8.27%	5.18%	5.12%
Operating Return on Assets (OROA)	9.88%	9.75%	10.06%	8.96%	9.88%	10.58%	9.67%	9.59%	9.49%	8.27%	8.54%
Return on Assets (ROA)	6.01%	6.00%	6.02%	6.15%	6.40%	7.05%	5.72%	6.32%	5.06%	5.33%	6.05%
Return on Common Equity (ROCE)	15.89%	15.36%	15.11%	15.23%	14.74%	15.39%	12.62%	13.56%	10.72%	12.55%	12.58%
Return on Equity Simple (ROE_SIMPLE)	-5.32%	-5.04%	0.00%	12.20%	11.89%	11.96%	0.00%	0.00%	0.00%	0.00%	0.00%
Net Operating Profit after Tax (NOPAT)	67	66	60	61	64	70	60	55	49	62	63
NOPAT Margin	23.44%	23.41%	21.79%	22.65%	22.55%	24.12%	20.21%	22.09%	17.75%	21.99%	22.32%
Net Nonoperating Expense Percent (NNEP)	1.03%	1.04%	0.90%	0.97%	0.86%	0.84%	0.95%	0.77%	0.66%	1.56%	0.92%
Return On Investment Capital (ROIC_SIMPLE)	-	2.36%	-	-	-	2.49%	2.09%	1.91%	1.70%	2.15%	2.15%
Cost of Revenue to Revenue	44.11%	44.14%	45.19%	45.34%	44.54%	44.53%	42.66%	43.76%	44.70%	44.48%	48.05%
SG&A Expenses to Revenue	9.08%	9.20%	9.55%	10.82%	9.19%	9.02%	9.12%	11.40%	10.23%	10.47%	10.75%
R&D to Revenue	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Operating Expenses to Revenue	25.07%	25.15%	25.15%	27.69%	25.74%	23.80%	27.51%	27.48%	26.23%	26.42%	25.14%
Earnings before Interest and Taxes (EBIT)	88	86	83	72	84	92	85	72	79	72	76
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)	97	95	92	80	92	99	92	80	87	81	85
Valuation Ratios	-	-	-	-	-	-	-	-	-	-	-
Price to Book Value (P/BV)	1.84	1.90	2.18	2.04	2.06	2.16	2.32	2.13	1.68	1.62	1.49
Price to Tangible Book Value (P/TBV)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Price to Revenue (P/Rev)	2.51	2.68	3.20	3.09	3.22	3.45	3.74	3.52	2.77	2.69	2.58
Price to Earnings (P/E)	0.00	0.00	17.21	16.75	17.35	18.03	19.84	18.52	15.29	15.91	14.74
Dividend Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Earnings Yield	0.00%	0.00%	5.81%	5.97%	5.76%	5.55%	5.04%	5.40%	6.54%	6.29%	6.79%
Enterprise Value to Invested Capital (EV/IC)	1.47	1.52	1.70	1.63	1.66	1.74	1.86	1.75	1.45	1.39	1.31
Enterprise Value to Revenue (EV/Rev)	3.58	3.69	4.17	4.04	4.12	4.32	4.57	4.32	3.59	3.60	3.47
Enterprise Value to EBITDA (EV/EBITDA)	252.46	257.55	12.37	12.36	12.72	13.29	14.29	13.31	11.11	11.68	11.34
Enterprise Value to EBIT (EV/EBIT)	0.00	0.00	13.66	13.71	14.11	14.64	15.66	14.57	12.17	12.89	12.59
Enterprise Value to NOPAT (EV/NOPAT)	0.00	0.00	18.06	17.71	18.22	18.95	20.43	19.42	17.04	17.63	16.50
Enterprise Value to Operating Cash Flow (EV/OCF)	17.98	17.34	18.84	17.61	17.39	18.81	20.66	17.55	15.12	14.37	14.65
Enterprise Value to Free Cash Flow (EV/FCFF)	15.20	14.85	17.80	17.26	17.72	20.15	23.22	19.82	17.51	27.30	26.03
Leverage & Solvency	-	-	-	-	-	-	-	-	-	-	-
Debt to Equity	0.82	0.75	0.68	0.65	0.61	0.57	0.56	0.56	0.57	0.59	0.55
Long-Term Debt to Equity	0.82	0.75	0.68	0.65	0.61	0.57	0.56	0.56	0.57	0.59	0.55
Financial Leverage	0.83	0.77	0.78	0.75	0.68	0.63	0.59	0.56	0.55	0.56	0.52
Leverage Ratio	2.22	2.16	2.15	2.10	2.04	1.97	1.93	1.91	1.90	1.89	1.85
Compound Leverage Factor	1.78	1.74	1.75	1.72	1.74	1.72	1.68	1.64	1.66	1.61	1.57
Debt to Total Capital	45.13%	42.96%	40.65%	39.52%	37.78%	36.32%	36.08%	35.79%	36.13%	36.92%	35.37%
Short-Term Debt to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Long-Term Debt to Total Capital	45.13%	42.96%	40.65%	39.52%	37.78%	36.32%	36.08%	35.79%	36.13%	36.92%	35.37%
Preferred Equity to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Noncontrolling Interests to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Common Equity to Total Capital	54.87%	57.04%	59.35%	60.48%	62.22%	63.68%	63.92%	64.21%	63.87%	63.08%	64.63%
Debt to EBITDA	79.01	74.29	2.99	3.02	2.92	2.81	2.85	2.84	2.88	3.15	3.10
Net Debt to EBITDA	75.25	70.37	2.87	2.92	2.78	2.67	2.58	2.46	2.55	2.96	2.91
Long-Term Debt to EBITDA	79.01	74.29	2.99	3.02	2.92	2.81	2.85	2.84	2.88	3.15	3.10
Debt to NOPAT	-88.59	-83.12	4.36	4.32	4.19	4.00	4.07	4.15	4.42	4.75	4.52
Net Debt to NOPAT	-84.38	-78.74	4.19	4.19	3.98	3.81	3.69	3.59	3.91	4.47	4.24
Long-Term Debt to NOPAT	-88.59	-83.12	4.36	4.32	4.19	4.00	4.07	4.15	4.42	4.75	4.52
Altman Z-Score	1.98	2.11	2.38	2.36	2.48	2.66	2.81	2.68	2.33	2.23	2.24
Noncontrolling Interest Sharing Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Liquidity Ratios	-	-	-	-	-	-	-	-	-	-	-
Current Ratio	2.99	3.09	3.20	3.23	3.56	3.68	4.20	4.38	3.70	3.11	3.57
Quick Ratio	1.68	1.87	1.91	1.80	2.01	2.13	2.74	2.81	2.36	1.81	2.12
Cash Flow Metrics	-	-	-	-	-	-	-	-	-	-	-
Free Cash Flow to Firm (FCFF)	347	362	64	67	71	55	29	50	42	-18	-21
Operating Cash Flow to CapEx	2,128.83%	3,580.76%	2,128.76%	4,754.86%	3,443.51%	4,156.51%	1,777.75%	9,428.76%	2,734.82%	2,585.44%	822.28%
Free Cash Flow to Firm to Interest Expense	19.71	21.85	4.20	5.11	5.79	4.79	2.73	4.91	4.23	-1.64	-1.82
Operating Cash Flow to Interest Expense	3.55	4.31	4.38	4.17	5.68	5.68	5.75	7.74	5.73	7.34	3.75
Operating Cash Flow Less CapEx to Interest Expense	3.38	4.19	4.18	4.08	5.52	5.55	5.43	7.66	5.52	7.05	3.29
Efficiency Ratios	-	-	-	-	-	-	-	-	-	-	-
Asset Turnover	0.32	0.32	0.34	0.33	0.33	0.34	0.34	0.33	0.33	0.32	0.32
Accounts Receivable Turnover	7.40	6.85	6.55	6.75	6.90	6.55	6.13	6.59	6.13	6.17	5.64
Inventory Turnover	3.37	3.31	3.33	3.09	3.13	3.34	3.51	3.22	3.09	3.07	3.21
Fixed Asset Turnover	16.03	16.21	15.32	15.31	15.25	15.54	15.06	15.02	15.00	10.94	11.10
Accounts Payable Turnover	10.10	9.80	9.85	10.21	13.17	17.06	17.38	15.91	13.34	15.51	23.64
Days Sales Outstanding (DSO)	49.30	53.32	55.75	54.04	52.91	55.74	59.52	55.41	59.58	59.16	64.74
Days Inventory Outstanding (DIO)	108.38	110.38	109.61	118.11	116.47	109.13	103.86	113.34	118.00	118.74	113.56
Days Payable Outstanding (DPO)	36.12	37.23	37.06	35.74	27.72	21.39	21.00	22.94	27.36	23.53	15.44
Cash Conversion Cycle (CCC)	121.56	126.47	128.30	136.40	141.67	143.48	142.38	145.81	150.22	154.36	162.86
Capital & Investment Metrics	-	-	-	-	-	-	-	-	-	-	-
Invested Capital	2,755	2,758	2,758	2,760	2,748	2,773	2,788	2,765	2,754	2,853	2,872
Invested Capital Turnover	0.39	0.39	0.41	0.40	0.40	0.40	0.41	0.41	0.40	0.39	0.38
Increase / (Decrease) in Invested Capital	-280	-296	-3.73	-6.61	-7.08	15	31	5.01	6.20	80	84
Enterprise Value (EV)	4,036	4,180	4,690	4,501	4,573	4,827	5,197	4,840	3,984	3,975	3,774
Market Capitalization	2,833	3,038	3,603	3,437	3,573	3,858	4,259	3,946	3,071	2,966	2,805
Book Value per Share	$31.00	$32.26	$33.34	$33.67	$34.94	$36.20	$37.04	$37.55	$37.08	$38.05	$39.89
Tangible Book Value per Share	($26.63)	($25.31)	($24.03)	($23.35)	($22.48)	($21.24)	($19.94)	($19.58)	($20.21)	($21.91)	($20.99)
Total Capital	2,799	2,806	2,789	2,779	2,783	2,809	2,871	2,890	2,857	2,900	2,920
Total Debt	1,263	1,206	1,134	1,098	1,052	1,020	1,036	1,034	1,032	1,071	1,033
Total Long-Term Debt	1,263	1,206	1,134	1,098	1,052	1,020	1,036	1,034	1,032	1,071	1,033
Net Debt	1,203	1,142	1,087	1,064	1,000	969	938	895	913	1,008	969
Capital Expenditures (CapEx)	2.93	2.00	3.14	1.15	2.03	1.57	3.48	0.84	2.10	3.03	5.21
Debt-free, Cash-free Net Working Capital (DFCFNWC)	198	203	212	220	222	224	244	231	244	231	247
Debt-free Net Working Capital (DFNWC)	258	266	258	255	274	275	342	371	363	294	311
Net Working Capital (NWC)	258	266	258	255	274	275	342	371	363	294	311
Net Nonoperating Expense (NNE)	14	13	11	11	9.62	8.99	9.81	7.67	6.43	16	8.93
Net Nonoperating Obligations (NNO)	1,219	1,157	1,103	1,079	1,016	985	954	910	929	1,023	985
Total Depreciation and Amortization (D&A)	8.96	9.07	9.36	8.58	8.36	7.30	7.69	8.11	8.11	8.04	8.81
Debt-free, Cash-free Net Working Capital to Revenue	17.61%	17.87%	18.80%	19.80%	20.01%	20.01%	21.43%	20.65%	21.95%	20.98%	22.66%
Debt-free Net Working Capital to Revenue	22.94%	23.48%	22.93%	22.87%	24.65%	24.56%	30.03%	33.11%	32.67%	26.63%	28.53%
Net Working Capital to Revenue	22.94%	23.48%	22.93%	22.87%	24.65%	24.56%	30.03%	33.11%	32.67%	26.63%	28.53%
Earnings Adjustments	-	-	-	-	-	-	-	-	-	-	-
Adjusted Basic Earnings per Share	$1.08	$1.07	$0.99	$0.98	$1.10	$1.23	$1.01	$0.96	$0.86	$0.98	$1.13
Adjusted Weighted Average Basic Shares Outstanding	49.69M	49.74M	49.76M	49.89M	49.65M	49.60M	49.70M	49.48M	49.03M	47.88M	48.46M
Adjusted Diluted Earnings per Share	$1.07	$1.06	$0.98	$0.98	$1.09	$1.22	$1.00	$0.95	$0.86	$0.97	$1.13
Adjusted Weighted Average Diluted Shares Outstanding	50.08M	50.13M	50.18M	50.27M	50.00M	49.99M	50.08M	49.83M	49.26M	48.09M	48.72M
Adjusted Basic & Diluted Earnings per Share	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding	49.62M	49.65M	49.92M	49.56M	49.41M	49.54M	49.41M	49.21M	48.08M	47.32M	47.37M
Normalized Net Operating Profit after Tax (NOPAT)	67	66	60	61	64	70	60	55	49	62	63
Normalized NOPAT Margin	23.44%	23.41%	21.79%	22.65%	22.55%	24.12%	20.21%	22.09%	17.75%	21.99%	22.32%
Pre Tax Income Margin	24.59%	24.61%	24.30%	21.87%	25.25%	27.61%	24.94%	24.76%	25.22%	21.81%	23.00%
Debt Service Ratios	-	-	-	-	-	-	-	-	-	-	-
EBIT to Interest Expense	5.00	5.20	5.41	5.45	6.84	8.00	7.87	7.05	7.89	6.79	6.67
NOPAT to Interest Expense	3.81	3.99	3.96	4.61	5.21	6.11	5.57	5.40	4.85	5.84	5.50
EBIT Less CapEx to Interest Expense	4.83	5.08	5.21	5.36	6.67	7.86	7.55	6.97	7.68	6.51	6.21
NOPAT Less CapEx to Interest Expense	3.65	3.87	3.75	4.52	5.05	5.98	5.25	5.32	4.64	5.56	5.04
Payout Ratios	-	-	-	-	-	-	-	-	-	-	-
Dividend Payout Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Augmented Payout Ratio	-30.58%	-30.99%	11.94%	12.66%	18.35%	18.79%	24.00%	28.31%	61.49%	89.49%	82.12%

Financials Breakdown Chart

Key Financial Trends

Prestige Consumer Healthcare (NYSE: PBH) showed steady revenue growth in fiscal 2026, but profitability and cash flow were shaped by higher costs, interest expense, and heavy share repurchases. Over the last several years, the company has generally delivered consistent mid-single-digit revenue performance, solid operating margins, and reliable operating cash flow. However, the balance sheet remains leveraged, and the business continues to carry substantial goodwill and intangible assets from prior acquisitions.

Revenue improved year over year in fiscal Q4 2026. Revenue rose to $281.6 million from $276.0 million in Q4 2025, while full-year quarterly comparisons also generally show a stable top line around the high-$200 million range.
Operating income remained strong. Q4 2026 operating income was $75.5 million, with an operating margin of about 26.8%, showing the company can still convert sales into healthy operating profit.
Operating cash flow was strong despite working-capital pressure. Q4 2026 operating cash flow was $42.8 million, and Q1–Q4 2026 operating cash generation remained solid overall.
Net income stayed positive and meaningful. Q4 2026 net income was $53.9 million, or $1.13 per share, reflecting continued earnings power.
The company has consistently produced positive earnings across the last four years shown. Even with some quarterly volatility, PBH has avoided the kind of earnings deterioration that often signals deeper operational stress.
Cash and equivalents increased sequentially in the latest quarter. Cash rose to $62.4 million at the end of Q3 2026 from $51.5 million at the end of Q2 2026, helped by operating performance.
Gross margin remains respectable, but not improving dramatically. Q4 2026 gross profit was $146.3 million on $281.6 million of revenue, indicating stable pricing and cost discipline, but not a major breakout in margin expansion.
Depreciation and amortization are manageable, but recurring. These non-cash charges are not overwhelming, yet they are a reminder of the company’s acquisition-heavy history.
Share count has been trending down through buybacks, helping EPS. The diluted share count has stayed below 50 million in recent quarters, supporting per-share earnings growth even when revenue is only modestly higher.
Goodwill and intangible assets make up most of the asset base. That is common for consumer healthcare companies with acquisition-led growth, but it also means the balance sheet is heavily dependent on acquired franchise value.
Debt remains high. As of Q3 2026, long-term debt was about $1.03 billion, with additional capital lease obligations, leaving leverage elevated relative to the company’s equity base.
Interest expense is still a significant drag on pre-tax earnings. Q4 2026 interest expense was $11.4 million, and other recent quarters have shown similar pressure.
Operating assets and liabilities created a negative working-capital swing in Q4 2026. That reduced operating cash flow versus net income and suggests some cash conversion noise quarter to quarter.
The company is spending heavily on share repurchases and debt repayment. In Q4 2026, it repaid $40.0 million of debt and bought back stock, which supports EPS but can limit flexibility if growth slows.
Operating cash flow was far weaker in Q3 2026 than Q4 2026. Q3 operating cash flow was helped or hurt by large quarter-specific working-capital items, showing that cash generation can be uneven.
Recent balance sheets show a sizable liability load versus equity. Total liabilities were $1.67 billion in Q3 2026 versus total equity of $1.83 billion, so the company is not lightly levered.

Bottom line: PBH looks like a steady, profitable consumer healthcare business with reliable cash generation and share-reduction support for EPS. The main caution is leverage: debt and interest expense remain meaningful, so future shareholder returns will depend on continued stable operating performance and disciplined capital allocation.

05/19/26 07:03 AM ETAI Generated. May Contain Errors.

Prestige Consumer Healthcare Financials - Frequently Asked Questions

According to the most recent income statement we have on file, Prestige Consumer Healthcare's financial year ends in March. Their financial year 2026 ended on March 31, 2026.

Prestige Consumer Healthcare's net income appears to be on an upward trend, with a most recent value of $190.30 million in 2026, rising from $99.91 million in 2016. The previous period was $214.61 million in 2025. View Prestige Consumer Healthcare's forecast to see where analysts expect Prestige Consumer Healthcare to go next.

Prestige Consumer Healthcare's total operating income in 2026 was $309.41 million, based on the following breakdown:

Total Gross Profit: $595.58 million
Total Operating Expenses: $286.17 million

Over the last 10 years, Prestige Consumer Healthcare's total revenue changed from $806.25 million in 2016 to $1.09 billion in 2026, a change of 35.0%.

Prestige Consumer Healthcare's total liabilities were at $1.61 billion at the end of 2026, a 2.5% increase from 2025, and a 27.1% decrease since 2016.

In the past 10 years, Prestige Consumer Healthcare's cash and equivalents has ranged from $27.19 million in 2022 to $97.88 million in 2025, and is currently $63.87 million as of their latest financial filing in 2026.

Over the last 10 years, Prestige Consumer Healthcare's book value per share changed from 14.11 in 2016 to 39.89 in 2026, a change of 182.7%.

Related Companies

Financial statements for NYSE:PBH last updated on 5/18/2026 by MarketBeat.com Staff. New filings and market data are monitored continuously.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Prestige Consumer Healthcare (PBH) Financials

Financials Breakdown Chart

Key Financial Trends

Prestige Consumer Healthcare Financials - Frequently Asked Questions

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Prestige Consumer Healthcare (PBH) Financials

Annual Income Statements for Prestige Consumer Healthcare

Quarterly Income Statements for Prestige Consumer Healthcare

Annual Cash Flow Statements for Prestige Consumer Healthcare

Quarterly Cash Flow Statements for Prestige Consumer Healthcare

Annual Balance Sheets for Prestige Consumer Healthcare

Quarterly Balance Sheets for Prestige Consumer Healthcare

Annual Metrics And Ratios for Prestige Consumer Healthcare

Quarterly Metrics And Ratios for Prestige Consumer Healthcare

Financials Breakdown Chart

Key Financial Trends

Prestige Consumer Healthcare Financials - Frequently Asked Questions

When does Prestige Consumer Healthcare's fiscal year end?

How has Prestige Consumer Healthcare's net income changed over the last 10 years?

What is Prestige Consumer Healthcare's operating income?

How has Prestige Consumer Healthcare's revenue changed over the last 10 years?

How much debt does Prestige Consumer Healthcare have?

How much cash does Prestige Consumer Healthcare have?

How has Prestige Consumer Healthcare's book value per share changed over the last 10 years?

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools